Treatment of Arsenical Refractory Rhodesian Sleeping Sickness in Kenya

Overview

Journal Ann Trop Med Parasitol

Specialties Parasitology
Tropical Medicine

Date 1989 Aug 1

PMID 2515816

Citations 7

Authors

J D Bales Jr

S M Harrison

D L Mbwabi

P J Schecter

Affiliations

Soon will be listed here.

Abstract

Case histories of three Rhodesian sleeping sickness patients who relapsed after Mel-B therapy are presented. Repeated Mel-B therapy was clinically effective but not curative, and all three patients subsequently relapsed again and required further treatment.

Citing Articles

The Drugs of Sleeping Sickness: Their Mechanisms of Action and Resistance, and a Brief History.

de Koning H Trop Med Infect Dis. 2020; 5(1).

PMID: 31963784 PMC: 7157662. DOI: 10.3390/tropicalmed5010014.

A luciferase based viability assay for ATP detection in 384-well format for high throughput whole cell screening of Trypanosoma brucei brucei bloodstream form strain 427.

Sykes M, Avery V Parasit Vectors. 2009; 2(1):54.

PMID: 19909542 PMC: 2781010. DOI: 10.1186/1756-3305-2-54.

Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to D,L-alpha-difluoromethylornithine.

Iten M, Mett H, Evans A, Enyaru J, Brun R, Kaminsky R Antimicrob Agents Chemother. 1997; 41(9):1922-5.

PMID: 9303385 PMC: 164036. DOI: 10.1128/AAC.41.9.1922.

In vivo trypanocidal activities of new S-adenosylmethionine decarboxylase inhibitors.

Bacchi C, Brun R, Croft S, Alicea K, Buhler Y Antimicrob Agents Chemother. 1996; 40(6):1448-53.

PMID: 8726018 PMC: 163348. DOI: 10.1128/AAC.40.6.1448.

In vitro trypanocidal activities of new S-adenosylmethionine decarboxylase inhibitors.

Brun R, Buhler Y, Sandmeier U, Kaminsky R, Bacchi C, Rattendi D Antimicrob Agents Chemother. 1996; 40(6):1442-7.

PMID: 8726017 PMC: 163347. DOI: 10.1128/AAC.40.6.1442.